Fulcrum Therapeutics

Bull case

• Fulcrum Therapeutics is supported by a substantial $333.3M cash, cash equivalents, and marketable securities position at the end of 1Q26, which should help limit near-term downside while management works to significantly reduce operating expenses and preserve capital.
• The completed dosing in the Phase 1b PIONEER trial and reported clinically relevant HbF induction, along with improvements in hemolysis and anemia markers, validate pociredir’s biological activity and support the broader rare-disease platform.
• Even though the prior pociredir-led SCD thesis is now less investable because the stock is increasingly tied to cash and strategic optionality, the company still has value if it can monetize assets, execute a thoughtful transaction, and leverage its public listing effectively.

Bear case

Fulcrum Therapeutics is facing a fundamentally weakened outlook because it discontinued pociredir in sickle cell disease after FDA feedback linked all PRC2 inhibition to a class-wide malignancy concern, despite the drug’s dose-dependent HbF gains and early improvements in hemolysis and anemia markers. The decision removes the company’s most advanced value driver, eliminates a viable regulatory path, and forces investors to focus instead on strategic alternatives, capital preservation, and the risk that further development of the broader platform will not offset the lost program. Although Fulcrum ended 1Q:26 with $333.3 million in cash, the abrupt loss of value from pociredir and the need to reduce operating expenses leave the stock exposed to dilution, uncertainty, and a much lower long-term fundamental profile.